From the Global IR Forum 2015: Cole Lannum, Mallinckrodt

Apr 25, 2016
<p>Former Covidien IRO Cole Lannum on his job transition to Mallinckrodt and the new scrutiny over specialty pharmaceuticals</p>

Cole Lannum, senior vice president of investor strategy at Covidien spin-off Mallinckrodt, discusses the challenges brought on by the changing environment for the specialty pharmaceuticals sector. The multiple awards winner gives his top tip for IROs: treat investors like customers, not adversaries.

Sign up to get stories direct to your inbox
logo-black logo-black